HIFU Prostate Cancer Treatment Patient Qualification | Maple Leaf HIFU

Find Out If You Qualify for HIFU

Non-invasive Prostate Cancer Treatment with Ablatherm® HIFU

The goal of Maple Leaf HIFU is to provide patients throughout North America with access to the latest proven treatment option available for localized prostate cancer: Ablatherm® High Intensity Focused Ultrasound.

To determine if you might be a candidate, we request information related to your condition. Please provide the following information (if available) and we will quickly respond. Alternatively, send us an e-mail to info@hifu.ca. To learn more, continue reading about the procedure.

Learn about HIFU Payment Plans

Title:	First name:	Last name:

Your age:	Telephone: (please include area code)	Email address:

PSA:

Cancer stage:

Gleason score:

Volume recorded on transrectal ultrasound (prostate size):

Have you been treated for prostate cancer in the past?
Yes No

If yes, how was your prostate cancer previously treated?

General comments:

Learn about HIFU Payment Plans

......................................................................................................................................

What is Ablatherm® HIFU?

Ablatherm® HIFU is a procedure where the temperature inside the prostate is raised to
85° Celsius (185° Fahrenheit) using a focused ultrasound beam. A probe is placed in the rectum after spinal anesthesia and sedation have been administered. This probe emits a beam of high intensity focused ultrasound. At the point where the ultrasound is focused (focal point), the sudden and intense absorption of the ultrasound beam quickly raises the temperature, which destroys targeted cells.

By using real-time integrated computer imaging of the prostate it is possible to move the focal point in a
systematic way that allows for complete destruction
of all prostate tissue. The treatment takes from
1 to 3 hours depending upon the size of the prostate
and is performed on an outpatient basis.

Is Ablatherm® HIFU a proven therapy?

Yes. In 1989, three prestigious European research groups united in their efforts and initiated a project to develop an efficient and non-surgical treatment for localized prostate cancer. After 10 years of development, the Ablatherm® HIFU was approved for treatment in Europe. At present the Ablatherm® HIFU is being used throughout Europe, Canada, England, Russia, and Asian countries. To date, tens of thousands of patients have been treated successfully in many European centers and throughout the world.

How do patients inquire about and arrange for treatment?

For additional information about Ablatherm® HIFU, please complete the form above.
One of our nurses will be back in touch with you soon.

Thanks again for visiting!

We look forward to speaking with you!